

Vincent Thibault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/725951/publications.pdf>

Version: 2024-02-01

144
papers

9,043
citations

61984

43
h-index

40979

93
g-index

147
all docs

147
docs citations

147
times ranked

7452
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver fibrosis in overweight patients. <i>Gastroenterology</i> , 2000, 118, 1117-1123.	1.3	861
2	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	27.0	683
3	Impact of hepatitis B and C virus on kidney transplantation outcome. <i>Hepatology</i> , 1999, 29, 257-263.	7.3	521
4	Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. <i>Hepatology</i> , 1999, 30, 1302-1306.	7.3	414
5	Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfecting patients: Impact of protease inhibitor therapy. <i>Hepatology</i> , 2001, 34, 283-287.	7.3	378
6	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 222-230.	3.7	322
7	Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. <i>Lancet</i> , The, 2001, 358, 718-723.	13.7	320
8	Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. <i>Hepatology</i> , 1998, 27, 868-872.	7.3	286
9	Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2004, 50, 1344-1355.	3.2	286
10	Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term follow-up study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3696-3706.	6.7	227
11	A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2006, 52, 1887-1896.	3.2	210
12	Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. <i>Aids</i> , 2003, 17, 721-725.	2.2	176
13	Interferon- γ and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3317-3326.	6.7	171
14	Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B Virus. <i>New England Journal of Medicine</i> , 2003, 348, 177-178.	27.0	157
15	Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of Determinant Variants. <i>Journal of Virology</i> , 2006, 80, 2968-2975.	3.4	153
16	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	0.9	136
17	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683.	3.7	134
18	Longitudinal Assessment of Histology Surrogate Markers (FibroTest-ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1970-1980.	0.4	128

#	ARTICLE	IF	CITATIONS
19	Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?. American Journal of Gastroenterology, 2006, 101, 1260-1267.	0.4	124
20	Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis and Rheumatism, 2004, 50, 3668-3678.	6.7	104
21	Hepatitis B virus genotypes and extrahepatic manifestations. Journal of Hepatology, 2005, 43, 764-770.	3.7	104
22	Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clinical Chemistry and Laboratory Medicine, 2004, 42, 323-33.	2.3	102
23	Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred. Journal of Hepatology, 2010, 52, 839-845.	3.7	102
24	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®] , [®]) and transient elastography (FibroScan [®]). Journal of Hepatology, 2014, 60, 706-714.	3.7	101
25	<i>In Vitro</i> Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir. Antiviral Therapy, 2004, 9, 353-363.	1.0	101
26	Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Aids, 2006, 20, 1157-1161.	2.2	95
27	Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology, 2003, 37, 1220-1221.	7.3	91
28	Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. Journal of Hepatology, 2006, 44, 62-67.	3.7	89
29	PegIFN \pm /ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of Hepatology, 2015, 62, 24-30.	3.7	86
30	Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. Journal of Viral Hepatitis, 2000, 7, 15-22.	2.0	82
31	Comparison of Hepatitis C Virus NS5b and 5' Noncoding Gene Sequencing Methods in a Multicenter Study. Journal of Clinical Microbiology, 2005, 43, 733-739.	3.9	81
32	Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis and Rheumatism, 2001, 44, 2118-2124.	6.7	78
33	TaqMan amplification system with an internal positive control for HCV RNA quantitation. Journal of Clinical Virology, 2004, 31, 227-234.	3.1	75
34	Primary infection with a lamivudine-resistant hepatitis B virus. Aids, 2002, 16, 131-133.	2.2	74
35	Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Coinfected with HBV and Human Immunodeficiency Virus. Journal of Clinical Microbiology, 1999, 37, 3013-3016.	3.9	69
36	Comparative Analysis of Translation Efficiencies of Hepatitis C Virus 5' Untranslated Regions among Intraindividual Quasispecies Present in Chronic Infection: Opposite Behaviors Depending on Cell Type. Journal of Virology, 2000, 74, 10827-10833.	3.4	68

#	ARTICLE	IF	CITATIONS
37	Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1586-1588.	3.2	66
38	An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. <i>PLoS ONE</i> , 2008, 3, e2573.	2.5	64
39	Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. <i>Aids</i> , 2009, 23, 2079-2089.	2.2	63
40	Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. <i>Journal of Hepatology</i> , 1999, 31, 598-603.	3.7	60
41	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	5.0	56
42	Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. <i>Journal of Viral Hepatitis</i> , 2006, 13, 329-335.	2.0	51
43	Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. <i>Aids</i> , 2004, 18, 75-79.	2.2	45
44	Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. <i>Aids</i> , 2002, 16, 713-717.	2.2	44
45	Human Leukocyte Antigen Class II Alleles May Contribute to the Severity of Hepatitis C Virus-Related Liver Disease. <i>Journal of Infectious Diseases</i> , 2002, 186, 106-109.	4.0	44
46	Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 847-858.	3.7	43
47	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514.	3.4	43
48	Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, .	2.3	42
49	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	3.7	42
50	Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3948-3953.	3.9	40
51	Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2250-2253.	3.9	36
52	Sequencing Assays for Failed Genotyping with the Versant Hepatitis C Virus Genotype Assay (LiPA), Version 2.0. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2815-2821.	3.9	35
53	Expertise of Laboratories in Viral Load Quantification, Genotyping, and Precore Mutant Determination for Hepatitis B Virus in a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3600-3607.	3.9	34
54	HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. <i>Fertility and Sterility</i> , 2010, 93, 1020-1023.	1.0	32

#	ARTICLE	IF	CITATIONS
55	Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. <i>Journal of Hepatology</i> , 2000, 33, 121-127.	3.7	30
56	Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. <i>Comparative Hepatology</i> , 2006, 5, 1.	0.9	30
57	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	3.7	28
58	Multicenter Quality Control for the Detection of Hepatitis C Virus RNA in Seminal Plasma Specimens. <i>Journal of Clinical Microbiology</i> , 2003, 41, 789-793.	3.9	27
59	Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1367-1373.	1.6	27
60	Tenofovir/probencid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?. <i>Aids</i> , 2010, 24, 1078-1079.	2.2	27
61	Hepatitis C Transmission in Injection Drug Users: Could Swabs Be the Main Culprit?. <i>Journal of Infectious Diseases</i> , 2011, 204, 1839-1842.	4.0	26
62	Molecular analysis of HBV genotypes and subgenotypes in the Central-East region of Tunisia. <i>Virology Journal</i> , 2010, 7, 302.	3.4	24
63	HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 204-213.	1.5	24
64	Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological Studies. <i>Journal of Clinical Microbiology</i> , 2006, 44, 614-616.	3.9	22
65	Chronic hepatitis E in HIV/HBV coinfecting patient. <i>Aids</i> , 2017, 31, 1346-1348.	2.2	22
66	Changing Electrolyte and Acido-Basic Profile in HIV-Infected Patients in the HAART Era. <i>Nephron Physiology</i> , 2006, 103, p131-p138.	1.2	21
67	Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men. <i>Aids</i> , 2008, 22, 658-661.	2.2	21
68	Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. <i>Antiviral Therapy</i> , 2011, 16, 199-205.	1.0	21
69	Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2195-2202.	3.9	21
70	European multicenter evaluation of Xpert® Xpress SARS-CoV-2/Flu/RSV test. <i>Journal of Medical Virology</i> , 2021, 93, 5798-5804.	5.0	21
71	Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification. <i>Journal of Clinical Virology</i> , 2015, 62, 32-37.	3.1	20
72	A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. <i>Virology Journal</i> , 2007, 4, 35.	3.4	19

#	ARTICLE	IF	CITATIONS
73	Potential Exposure to Hepatitis C Virus through Accidental Blood Contact in Interventional Radiology. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, 173-179.	0.5	18
74	Performance of the DiaSorin LIAISON [®] anti-HBs II for the detection of hepatitis B surface antibodies: Comparison with the Abbott Architect anti-HBs assay. <i>Journal of Clinical Virology</i> , 2011, 50, 297-302.	3.1	18
75	Could Droplet Digital PCR Be Used Instead of Real-Time PCR for Quantitative Detection of the Hepatitis B Virus Genome in Plasma?. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3497-3498.	3.9	18
76	Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. <i>Journal of Clinical Virology</i> , 2017, 89, 14-21.	3.1	18
77	Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon- α 2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2008, 13, 895-900.	1.0	18
78	Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 422-424.	0.9	17
79	Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injury. <i>Cytokine</i> , 2018, 111, 500-504.	3.2	16
80	Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure. <i>Gut</i> , 2003, 52, 614-a-614.	12.1	15
81	Expertise of French Laboratories in Detection, Genotyping, and Quantification of Hepatitis C Virus RNA in Serum. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2027-2030.	3.9	15
82	Multicenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load Determination. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3788-3790.	3.9	15
83	Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1750-1756.	2.8	15
84	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	3.7	15
85	A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. <i>Journal of Viral Hepatitis</i> , 2006, 13, 182-189.	2.0	14
86	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503.	2.3	14
87	The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2003, 10, 103-110.	2.0	13
88	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. <i>Aids</i> , 2004, 18, 123-127.	2.2	13
89	Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous anti-hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1356-1359.	2.2	13
90	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	2.5	13

#	ARTICLE	IF	CITATIONS
91	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	3.3	13
92	Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. <i>Journal of Virological Methods</i> , 2000, 85, 117-124.	2.1	12
93	Fatal fulminant primary hepatitis B virus infections with G1896A precore viral mutants in southeastern France. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e1-e8.	1.5	11
94	Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. <i>Journal of Viral Hepatitis</i> , 2015, 22, 718-726.	2.0	11
95	Respiratory Influenza viral load as a marker of poor prognosis in patients with severe symptoms. <i>Journal of Clinical Virology</i> , 2021, 136, 104761.	3.1	11
96	Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification Limits. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1113-1115.	3.9	10
97	Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013, 58, 385-390.	3.1	10
98	Molecular Epidemiology and Clinical Characteristics of Hepatitis B Identified through the French Mandatory Notification System. <i>PLoS ONE</i> , 2013, 8, e75267.	2.5	10
99	Contribution of quantitative viral markers to document hepatitis B virus compartmentalization in cerebrospinal fluid during hepatitis B with neuropathies. <i>Journal of NeuroVirology</i> , 2018, 24, 769-772.	2.1	10
100	Characterization and Biologic Activities of Recombinant Rat Soluble Interleukin-6 Receptor. <i>Journal of Interferon and Cytokine Research</i> , 1996, 16, 973-981.	1.2	9
101	Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: Results from a randomized control trial. <i>Hepatology</i> , 2002, 35, 238-239.	7.3	9
102	Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. <i>Journal of Virological Methods</i> , 2009, 159, 265-270.	2.1	9
103	Genotype 4 hepatitis C virus: Beware of false-negative RNA detection. <i>Hepatology</i> , 2011, 53, 1066-1067.	7.3	9
104	Lack of TGF- β 2 production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. <i>Journal of Hepatology</i> , 2012, 56, 1259-1268.	3.7	9
105	Too Often Forgotten: Passive Transfer of Antibodies: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 709-710.	5.8	9
106	The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. <i>Journal of Clinical Virology</i> , 2020, 129, 104507.	3.1	9
107	Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. <i>Aids</i> , 2001, 15, 2463-2464.	2.2	9
108	Efficient and Quality-Optimized Metagenomic Pipeline Designed for Taxonomic Classification in Routine Microbiological Clinical Tests. <i>Microorganisms</i> , 2022, 10, 711.	3.6	9

#	ARTICLE	IF	CITATIONS
109	Low Levels of Hepatitis C Virus (HCV) Neutralizing Antibodies in Patients Coinfected with HCV and Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2008, 198, 332-335.	4.0	8
110	Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. <i>Virology Journal</i> , 2013, 10, 87.	3.4	8
111	Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. <i>Antiviral Therapy</i> , 2008, 13, 895-900.	1.0	8
112	Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. <i>Journal of Clinical Virology</i> , 2013, 58, 408-414.	3.1	7
113	Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. <i>Antiviral Therapy</i> , 2006, 11, 1103-6.	1.0	7
114	Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	7
115	Adjustment of antiretroviral regimen may lead to HBV reactivation even in patients with past HBV infection serological profile. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 987-989.	1.7	6
116	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. <i>Journal of Clinical Virology</i> , 2015, 69, 203-209.	3.1	6
117	High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 678-681.	2.5	6
118	Combined use of dried blood spot and rapid molecular systems: A robust solution to monitor hepatitis B virus infection with potential for resource-limited countries. <i>Journal of Virological Methods</i> , 2020, 283, 113908.	2.1	5
119	Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation. <i>FEBS Letters</i> , 1997, 408, 182-186.	2.8	4
120	Performance comparison of new Veris and Xpert random access HIV-1 RNA quantification assays. <i>Virology Journal</i> , 2018, 15, 156.	3.4	4
121	A Highly Prevalent Polymorphism in the Core Region Impairs Quantification of Hepatitis B Virus (HBV) by the cobas TaqMan HBV Assay. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	4
122	Construction and Characterization of a Replication-Deficient Adenovirus Expressing Rat-Soluble Interleukin-6 Receptor. <i>Molecular Medicine</i> , 1997, 3, 519-529.	4.4	3
123	Hepatitis C Virus Infection in Long-term Nonprogressor HIV-1-Infected Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 204-206.	2.1	3
124	Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon- α 2a in a patient with HIV/HCV co-infection. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 937-938.	1.7	3
125	Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1428-1433.	3.9	3
126	Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 145-147.	8.1	3

#	ARTICLE	IF	CITATIONS
127	Performances of NeuMoDx [®] , a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1693.e9-1693.e15.	6.0	3
128	Editorial: HBV cure—the quest for biomarkers to predict off-treatment sustained response. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 552-554.	3.7	3
129	Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology. <i>Future Virology</i> , 2006, 1, 553-565.	1.8	2
130	Hepatitis E infection in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1367-1371.	1.6	2
131	Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 302-309.	1.6	2
132	Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD). <i>Journal of Hepatology</i> , 2018, 68, S99-S100.	3.7	2
133	When a viral eruption hides another one: intrafamilial outbreak of parvovirus B19 and measles virus co-infections: case report. <i>BMC Infectious Diseases</i> , 2020, 20, 496.	2.9	2
134	Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. <i>Journal of Hepatology</i> , 2002, 36, 18.	3.7	1
135	Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1276-1283.	2.0	1
136	Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0174651.	2.5	1
137	Short-term survival of acute respiratory distress syndrome patients due to influenza virus infection alone: a cohort study. <i>ERJ Open Research</i> , 2020, 6, 00587-2020.	2.6	1
138	More on HBe Ag-negative mutants in chronic HBV infection. <i>Clinical Microbiology and Infection</i> , 1997, 3, 590-591.	6.0	0
139	Quantitative HBV-DNA testing: are we ready for international units?. <i>Journal of Hepatology</i> , 2002, 36, 132.	3.7	0
140	Long term use of adefovir in HIV-HBV coinfecting patients is not associated with emergence of specific HBV polymerase mutations. <i>Journal of Hepatology</i> , 2002, 36, 132-133.	3.7	0
141	Use of Inno-Lipa HBV-DR to assess the sensitivity of lamivudine-resistant HBV mutants to adefovir. <i>Journal of Hepatology</i> , 2002, 36, 133.	3.7	0
142	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2003, 124, A763.	1.3	0
143	Comparison of Viral replication fitness of wild-type and lamivudine-resistant HBV in patients. <i>Gastroenterology</i> , 2003, 124, A709.	1.3	0
144	Influence of preanalytical parameters on influenza and respiratory syncytial virus molecular detection. <i>Journal of Clinical Virology</i> , 2022, 147, 105063.	3.1	0